Beigene Stock News

BeiGene Ltd - ADR (BGNE) shares closed today 10.0% lower than it did at the end of yesterday. The stock is currently down 18.2% year-to-date, down 17.6% over the past 12 months, and up 614.3% over the past five years. Today, the Dow Jones Industrial Average fell 1.0%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $279.96 and as low as $220.40 this week.Shares closed 48.1% below its 52-week high and 0.5% above its 52-week low.Trading volume this week was 31.5% higher than the 10-day average and 8.8% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3326.6% The company's stock price performance over the past 12 months lags the peer average by 28.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

BeiGene Ltd - ADR (BGNE) shares closed today at 0.5% above its 52 week low of $220.40, giving the company a market cap of $22B. The stock is currently down 18.2% year-to-date, down 17.6% over the past 12 months, and up 614.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 8.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3326.6% The company's stock price performance over the past 12 months lags the peer average by 28.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

Banque Cantonale Vaudoise reduced its position in BeiGene, Ltd. (NASDAQ:BGNE) by 51.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,161 shares of the company’s stock after selling 1,233 shares during the quarter. Banque Cantonale Vaudoise’s holdings in […]

Bank of America Corp DE lifted its position in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 6.9% during the second quarter, HoldingsChannel reports. The fund owned 273,730 shares of the companys stock after acquiring an additional 17,715 shares during the quarter. Bank of America Corp DEs holdings in BeiGene were worth $93,940,000 as of its most []

As U.S. Takes Aim At China Drug Makers, Innovators Appear At Biggest Risk

BeiGene Ltd. said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis oncology treatments in China. "Ociperlimab is an investigational potent TIGIT inhibitor with intact Fc function, believed to be critical for the anti-tumor activities of TIGIT antibodies," the companies said in a joint statement. Beijing-based BeiGene will receive an upfront payment of $300 million up to $700 million more on exercise by Novartis of a time-based option prior to mid-2023. After that it will be eligible for up to $745 million for reaching certain regulatory milestones, and $1.15 billion for sales milestones and royalties. U.S.-listed shares of BeiGene were up 2.3% premarket. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Basel, December 20, 2021 Novartis announced today the signing of an option, collaboration and license agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), expanding the companys research and development activities in immuno-oncology. Ociperlimab is a late-stage TIGIT inhibitor, a novel class of anti-cancer therapies that blocks the TIGIT protein receptor. Ociperlimab is currently being evaluated in two Phase III lung cancer trials and additional studies are ongoing in a wide range of solid tumors.

BeiGene Ltd (NASDAQ: BGNE) announced an option, collaboration, and license agreement with Novartis AG (NYSE: NVS) to develop, manufacture, and commercialize BeiGene's ociperlimab in North America

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces the official launch of the BeiGene Bioisland Innovation Center (BIC), an innovator-centric incubator in Guangzhou, China.

BeiGene Ltd. BGNE, +0.25% said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG NVS, -0.20% to develop its investigational TIGIT inhibitor ociperlimab in North America, Eu

-- Clare Fisher, accomplished corporate and business development executive and current svp of business development and mergers & acquisitions at BeiGene, will join the Board effective January 1, 2022 -- -- Judith J. Li, partner at Lilly Asia Ventures, will depart the Board effective January 1, 2022 --

Kestra Advisory Services LLC increased its position in BeiGene, Ltd. (NASDAQ:BGNE) by 2.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,105 shares of the companys stock after buying an additional 59 shares during the quarter. Kestra Advisory Services LLCs holdings in BeiGene []